Previous 10 | Next 10 |
WATERTOWN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the Company will present at the 41 st Ann...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips New Year 2023 will see a continued tightening of monetary policy as the Federal Reserve attempts to rein in sky-high inflation. Following the 50 basis point rate hike in Dec., there are expectations that Feb. and March will ...
Investors were optimistic on Wednesday, sending the Nasdaq Composite (NASDAQINDEX: ^IXIC) up a third of a percent as of 1 p.m. ET. Even with most market participants focused on monetary policy and the Federal Reserve, long-term investors kept their eyes squarely on positive developments f...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: arfa adam / Shutterstock.com Drive Shack (NYSE: DS ) stock is falling hard on Wednesday after the company warned investors of it delisting shares . According to a press release, Drive Shack intends to del...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: shutterstock.com/rafapress SoFi Technologies (NASDAQ: SOFI ) stock is climbing higher on Wednesday after the company’s CEO bought more shares. Anthony Noto, CEO of SoFi Technologies, purchased an ad...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: iQoncept / Shutterstock Crown Electrokinetics (NASDAQ: CRKN ) stock is on the move Wednesday as investors prepare for the company’s upcoming shareholder meeting . That meeting will take place on De...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Gorodenkoff / Shutterstock.com What’s trending in the pharmaceutical sector today? In a fresh press release, Kymera Therapeutics (NASDAQ: KYMR ) disclosed positive results from its clinical trial for a sk...
Kymera Therapeutics ( NASDAQ: KYMR ) reported data from a patient group portion of its drug KT-474 (IRAK4) from a phase 1 trial, and updates on its three oncology programs: KT-413 (IRAKIMiD), KT-333 (STAT3) and KT-253 (MDM2). KT-474 : The company said Part C of its KT...
KT-474 Phase 1 clinical data in HS and AD patients demonstrate robust IRAK4 knockdown in blood and active skin lesions and systemic suppression of proinflammatory cytokines and chemokines with a favorable safety profile Clinical endpoints addressing disease burden and symptoms demonstra...
Activity of STAT3 degrader in preclinical model of cutaneous T-cell lymphoma (CTCL) validates selective STAT3 degradation as a potential therapeutic strategy for STAT3-driven T cell malignancies Preclinical study highlights the potential of IRAKIMiDs combined with BCL-2 inhibitor as a t...
News, Short Squeeze, Breakout and More Instantly...
Kymera Therapeutics Inc. Company Name:
KYMR Stock Symbol:
NASDAQ Market:
Kymera Therapeutics Inc. Website:
2024-07-12 19:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 13:30:00 ET Shares of Kymera Therapeutics (NASDAQ: KYMR) were soaring 18.4% higher as of 11:28 a.m. ET on Tuesday. The big jump came after the clinical-stage biopharmaceutical company announced on Monday that its partner, Sanofi , plans to expand the ongoing phase 2 s...
WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside ...